Sura, S.; Bupathi, M.; Morris, V.; Conkling, P.; Todoroff, K.; Bhanegaonkar, A.; Ike, C.
Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study. Curr. Oncol. 2025, 32, 187.
https://doi.org/10.3390/curroncol32040187
AMA Style
Sura S, Bupathi M, Morris V, Conkling P, Todoroff K, Bhanegaonkar A, Ike C.
Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study. Current Oncology. 2025; 32(4):187.
https://doi.org/10.3390/curroncol32040187
Chicago/Turabian Style
Sura, Sneha, Manojkumar Bupathi, Valerie Morris, Paul Conkling, Karen Todoroff, Abhijeet Bhanegaonkar, and Chiemeka Ike.
2025. "Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study" Current Oncology 32, no. 4: 187.
https://doi.org/10.3390/curroncol32040187
APA Style
Sura, S., Bupathi, M., Morris, V., Conkling, P., Todoroff, K., Bhanegaonkar, A., & Ike, C.
(2025). Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study. Current Oncology, 32(4), 187.
https://doi.org/10.3390/curroncol32040187
